Form 4: Heartflow Officer Trades Common Stock

Heartflow, Inc. Chief Medical Officer Campbell Rogers reports significant transactions involving common stock, including option exercises and sales, executed under a Rule 10b5-1 trading plan.

Summary

• Campbell Rogers, Chief Medical Officer of Heartflow, Inc., reported a series of transactions on April 1, 2026.
• These transactions involved the exercise of stock options and the sale of common stock.
• A total of 291 shares were acquired at $8.33 and 19,111 shares at $2.22, with these transactions being part of a Rule 10b5-1 trading plan.
• Additionally, 40,766 shares were acquired at $2.22 and 6,849 shares at $2.22, also under a Rule 10b5-1 plan.
• A sale of 64,533 shares occurred at a weighted average price of $24.64, with individual trade prices ranging from $24.03 to $25.27.
• This sale also included shares acquired through option exercises as part of the Rule 10b5-1 plan.
• Following these transactions, Rogers beneficially owns 81,002 shares directly, with additional holdings indirectly through various trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While significant share sales by an executive can sometimes be perceived negatively, the execution under a Rule 10b5-1 plan suggests a pre-determined strategy rather than a reaction to negative company news.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned and potentially less market-sensitive trading activity.
• The weighted average sale price of $24.64 suggests a profitable exit for a portion of the shares, significantly higher than the exercise prices of the options.

Negatives

• A substantial number of shares (64,533) were sold, which could be interpreted as a lack of confidence in near-term stock appreciation by a key executive.
• The sale price, while profitable, is lower than the peak prices the stock may have achieved previously, though this is not explicitly stated in the filing.

Risks

• The filing does not explicitly mention any risks associated with these transactions.
• However, the sale of a significant number of shares by a key executive could be perceived negatively by the market, potentially impacting share price.

Future Outlook

The filing is a statement of changes in beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future financial performance.

Management Comments

• The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.
• Includes the sale of 16,918 shares of common stock held and the option exercise and sale of 47,615 shares reported on this Form 4 that were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.
• The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by a Chief Medical Officer at a company like Heartflow, Inc. is common practice to diversify holdings or manage personal finances while adhering to insider trading regulations.

Stakeholder Impact

• Shareholders may view the sale of a significant number of shares by the Chief Medical Officer with caution, potentially leading to short-term share price pressure.
• Employees may interpret the sale as a signal from management, though the Rule 10b5-1 plan mitigates this concern.
• Creditors and suppliers are unlikely to be directly impacted by this insider transaction.

Next Steps

• The reporting person will continue to hold shares indirectly through various trusts.
• Future transactions, if any, will be reported on subsequent Form 4 filings.

Key Dates

Recommendation

The filing details insider transactions executed under a pre-established Rule 10b5-1 plan. While the sale of a significant number of shares by a key executive warrants attention, the structured nature of the trades suggests it's part of personal financial planning rather than a reflection of negative company outlook. Without further information on the company's performance or future prospects, a 'hold' recommendation is prudent, advising investors to monitor future filings and company announcements.

Keywords

Form 4, SEC Filing, Heartflow Inc., HTFL, Campbell Rogers, Chief Medical Officer, Stock Options, Common Stock, Beneficial Ownership, Rule 10b5-1, Insider Trading, Securities Transaction